Clinical Trial Update: BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL [Phase 1]

View source ↗

Summary

This ClinicalTrials.gov entry reports a Phase 1 study of BAFFR-targeting CAR T cells for relapsed or refractory B-cell non-Hodgkin lymphoma, currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• BAFFR-targeting CAR-T cells

Snippet

Sponsor: PeproMene Bio, Inc. | Conditions: Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | Phase 1 | Status: RECRUITING